

# Histamine Increases Cytosolic $\text{Ca}^{2+}$ in Dibutylrlyl-cAMP-Differentiated HL-60 Cells via $\text{H}_1$ Receptors and Is an Incomplete Secretagogue

ROLAND SEIFERT, ARIANE HÖER, STEFAN OFFERMANN, ARMIN BUSCHAUER, and WALTER SCHUNACK

*Institut für Pharmakologie, Universitätsklinikum Rudolf Virchow, Freie Universität Berlin, D-1000 Berlin 33, Germany (R.S., A.H., S.O.), and Institut für Pharmazie, Freie Universität Berlin, D-1000 Berlin 33, Germany (A.B., W.S.)*

Received July 10, 1991; Accepted May 4, 1992

## SUMMARY

Human neutrophils and dibutylrlyl-cAMP ( $\text{Bt}_2\text{cAMP}$ )-differentiated HL-60 cells possess receptors for the chemotactic peptide *N*-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMet-Leu-Phe), which mediate activation of phospholipase C, with subsequent increase in cytosolic  $\text{Ca}^{2+}$  concentration ( $[\text{Ca}^{2+}]_i$ ) and activation of specific cell functions. In many cell types, histamine, via  $\text{H}_1$  receptors, activates phospholipase C, but it is unknown whether neutrophilic cells possess functional  $\text{H}_1$  receptors. We compared the effects of histamine with those of fMet-Leu-Phe on activation of these cells. In  $\text{Bt}_2\text{cAMP}$ -differentiated HL-60 cells, substances increased  $[\text{Ca}^{2+}]_i$  in the effectiveness order fMet-Leu-Phe > histamine > betahistamine. Pertussis toxin diminished fMet-Leu-Phe-induced rises in  $[\text{Ca}^{2+}]_i$  to a greater extent than those induced by histamine.  $\text{H}_1$  but not  $\text{H}_2$  antagonists inhibited histamine- and betahistamine-induced rises in  $[\text{Ca}^{2+}]_i$ . fMet-Leu-Phe and histamine activated phospholipase C and increased  $[\text{Ca}^{2+}]_i$  through release of  $\text{Ca}^{2+}$  from intracellular stores and sustained

influx of  $\text{Ca}^{2+}$  from the extracellular space. The substances also induced  $\text{Mn}^{2+}$  influx.  $\text{Ca}^{2+}$  and  $\text{Mn}^{2+}$  influxes were inhibited by 1- $\beta$ -[3-(4-methoxyphenyl)propoxyl]-4-methoxyphenethyl-1*H*-imidazole hydrochloride (SK&F 96365). The stimulatory effects of histamine on  $[\text{Ca}^{2+}]_i$  were more sensitive to inhibition by 4 $\beta$ -phorbol 12-myristate 13-acetate than were those of fMet-Leu-Phe. Unlike fMet-Leu-Phe, histamine did not activate superoxide anion formation, release of  $\beta$ -glucuronidase, and tyrosine phosphorylation. In neutrophils, histamine and betahistamine did not induce rises in  $[\text{Ca}^{2+}]_i$ . Our data show that (i) in  $\text{Bt}_2\text{cAMP}$ -differentiated HL-60 cells, histamine increases  $[\text{Ca}^{2+}]_i$  via  $\text{H}_1$  receptors coupled to pertussis toxin-sensitive and possibly, pertussis toxin-insensitive heterotrimeric regulatory guanine nucleotide-binding proteins, (ii) histamine activates nonselective cation channels, and (iii) unlike fMet-Leu-Phe, histamine is an incomplete secretagogue.

The intercellular signal molecule histamine mediates its effects through  $\text{H}_1$ ,  $\text{H}_2$ , and  $\text{H}_3$  receptors (1, 2). Stimulation of  $\text{H}_1$  receptors results in the activation of phospholipase C, which catalyzes phosphoinositide degradation to diacylglycerol and  $\text{InsP}_3$ ; diacylglycerol activates protein kinase C, and  $\text{InsP}_3$  mobilizes  $\text{Ca}^{2+}$  from intracellular stores, resulting in an increase in  $[\text{Ca}^{2+}]_i$  (1-3).  $\text{H}_1$  Receptors interact with pertussis toxin-sensitive or pertussis toxin-insensitive G proteins, depending on the cell type studied (3-7).  $\text{H}_2$  Receptors interact with the G protein  $\text{G}_s$ , leading to the activation of adenylyl cyclase, with subsequent increase in cAMP (1-3).

Neutrophilic cells, i.e., neutrophils and differentiated HL-60 cells, possess receptors for the chemotactic peptide fMet-Leu-

Phe, which couple to pertussis toxin-sensitive G proteins (8-20). fMet-Leu-Phe induces activation of phospholipase C, phosphorylation of tyrosine, and opening of nonselective cation channels, which mediate sustained influx of  $\text{Ca}^{2+}$  from the extracellular space (8-10, 20-22). Exposure of these cells to fMet-Leu-Phe culminates in activation of NADPH oxidase-catalyzed  $\text{O}_2^-$  formation and in release of  $\beta$ -glucuronidase from azurophilic granules (8-10, 13, 23, 24). Neutrophilic cells and HL-60 promyelocytes possess  $\text{H}_2$  receptors; activation of these receptors leads to inhibition of fMet-Leu-Phe-stimulated  $\text{O}_2^-$  formation and induction of cell differentiation, respectively (25-31). It is, however, unknown whether human myeloid cells possess functional  $\text{H}_1$  receptors, although the results of binding studies suggested the presence of such receptors (32-34). By analogy to formyl peptide receptors, activation of  $\text{H}_1$  receptors in myeloid cells would be expected to result in increases in

This work was supported by grants from the Deutsche Forschungsgemeinschaft and the Fonds der Chemischen Industrie.

**ABBREVIATIONS:**  $\text{InsP}_3$ , inositol trisphosphate;  $\text{Bt}_2\text{cAMP}$ , dibutylrlyl-cAMP;  $[\text{Ca}^{2+}]_i$ , cytosolic  $\text{Ca}^{2+}$  concentration; EGTA, ethylene bis(oxyethylenetriol)tetraacetic acid; G protein, heterotrimeric regulatory guanine nucleotide-binding protein; fMet-Leu-Phe, *N*-formyl-L-methionyl-L-leucyl-L-phenylalanine; fura-2/AM, fura-2/acetoxymethyl ester;  $\text{O}_2^-$ , superoxide anion; PDD, 4 $\alpha$ -phorbol-12,13-didecanoate; PMA, 4 $\beta$ -phorbol 12-myristate 13-acetate; SK&F 96365, 1- $\beta$ -[3-(4-methoxyphenyl)propoxyl]-4-methoxyphenethyl-1*H*-imidazole hydrochloride; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.

[Ca<sup>2+</sup>]<sub>i</sub> and stimulation of O<sub>2</sub><sup>-</sup> formation. We and others could not obtain evidence to support the assumption that H<sub>1</sub> receptors play a part in the activation of O<sub>2</sub><sup>-</sup> formation in human neutrophils (27, 29).

HL-60 cells differentiated towards neutrophils with Bt<sub>2</sub>cAMP are a widely used model system to study signal transduction processes in human myeloid cells (11–16, 18). Among other receptors, these cells very effectively express functional ATP and UTP receptors (12–15). These receptors couple to both pertussis toxin-sensitive and pertussis toxin-insensitive G proteins, leading to activation of phospholipase C (12–15, 18). In Bt<sub>2</sub>cAMP-differentiated HL-60 cells, ATP and UTP *per se* stimulate O<sub>2</sub><sup>-</sup> formation and β-glucuronidase release, whereas in human neutrophils they do not (12, 13, 24).

All these findings prompted us to address the question of whether Bt<sub>2</sub>cAMP-differentiated HL-60 cells provide a suitable model system to study H<sub>1</sub> receptors in human myeloid cells. We show here that histamine, via H<sub>1</sub> receptors, increases [Ca<sup>2+</sup>]<sub>i</sub> in Bt<sub>2</sub>cAMP-differentiated HL-60 cells and that histamine is an incomplete secretagogue.

## Experimental Procedures

**Materials.** Pertussis toxin was donated by Dr. M. Yajima (Kaken Pharmaceutical, Otsu, Japan). SK&F 96365 was a gift of Dr. D. Arndts (Boehringer Ingelheim, Ingelheim, Germany). Clemastine, chlorpheniramine, diphenhydramine, and famotidine were purchased from Sigma Chemie (Taufkirchen, Germany). *myo*-[2-<sup>3</sup>H]inositol (10–20 Ci/mmol) was purchased from Amersham-Buchler (Braunschweig, Germany). Monoclonal antiphosphotyrosine antibody PY-20 (IgG2B) was from ICN (Meckenheim, Germany). Sources of other materials have been described elsewhere (12, 13, 24, 29–31, 35).

**Cell culture.** HL-60 cells were grown in suspension culture in RPMI 1640 medium supplemented with 10% (v/v) horse serum, 1% (v/v) nonessential amino acids, 2 mM L-glutamine, 50 units/ml penicillin, and 50 μg/ml streptomycin, in a humidified atmosphere with 7% CO<sub>2</sub> at 37°. To induce differentiation, HL-60 cells were seeded at 1 × 10<sup>6</sup> cells/ml and were cultured for 48 hr with 0.2 mM Bt<sub>2</sub>cAMP (12, 13).

**Pertussis toxin treatment of HL-60 cells.** Differentiation of HL-60 cells was induced as described above. Twenty-four hours before experiments, pertussis toxin (1 μg/ml) or its vehicle (control) was added to the cell cultures. Under these conditions, pertussis toxin functionally inactivated >98% of the cellular content of pertussis toxin-sensitive G proteins (15, 23).

**Isolation of human neutrophils.** Neutrophils were isolated from buffy coats from the local blood bank or from fresh blood of individual healthy volunteers (24, 29, 30). Cell preparations consisted of >95% viable neutrophils, as revealed by trypan blue dye exclusion and Papenheim-stained smears.

**Measurement of [Ca<sup>2+</sup>]<sub>i</sub>.** [Ca<sup>2+</sup>]<sub>i</sub> was determined with the dye fura-2/AM, as described (13), with modifications. HL-60 cells or neutrophils were suspended at 1 × 10<sup>7</sup> cells/ml in a buffer consisting of (in mM) 138 NaCl, 6 KCl, 1 MgSO<sub>4</sub>, 1 Na<sub>2</sub>HPO<sub>4</sub>, 5 NaHCO<sub>3</sub>, 5.5 glucose, and 20 HEPES-NaOH, pH 7.4, supplemented with 0.1% (w/v) bovine serum albumin. Fura-2/AM was added at a concentration of 4 μM, and cells were incubated for 10 min at 37°. Thereafter, cells were diluted with the aforementioned buffer to a concentration of 5 × 10<sup>6</sup> cells/ml and were incubated for 45 min at 37°. Subsequently, cells were diluted with the aforementioned buffer to a final concentration of 0.5 × 10<sup>6</sup> cells/ml and were centrifuged at 250 × *g* for 10 min at 20°. Cells were suspended at 1.0 × 10<sup>6</sup> cells/ml in the aforementioned buffer and were kept at 20° until measurement of [Ca<sup>2+</sup>]<sub>i</sub>. HL-60 cells were used for up to 4 hr after loading with fura-2/AM (14). HL-60 cells or neutrophils (1.0 × 10<sup>6</sup> cells) were suspended in 2 ml of the aforementioned buffer, using acryl fluorescence cuvettes (Sarstedt, Nümbrecht, Germany).

Fluorescence was determined at 37°, with constant stirring of the cells at 1 × 10<sup>3</sup> rpm, using a Ratio II spectrofluorometer (Aminco, Silver Spring, MD). Cells were incubated for 3 min at 37°, in the absence or presence of various substances (e.g., histamine receptor antagonists), before the addition of stimuli; basal fluorescence (basal [Ca<sup>2+</sup>]<sub>i</sub>) was measured for 1 min. The excitation and emission wavelengths were 340 and 500 nm, respectively. Basal [Ca<sup>2+</sup>]<sub>i</sub> values and peak [Ca<sup>2+</sup>]<sub>i</sub> values stimulated by agonists were calculated according to eq. 6 given in Ref. 36. Basal [Ca<sup>2+</sup>]<sub>i</sub> values were subtracted from the corresponding peak [Ca<sup>2+</sup>]<sub>i</sub> values, to calculate the increase in [Ca<sup>2+</sup>]<sub>i</sub> induced by a given stimulus. Influx of Mn<sup>2+</sup> into HL-60 cells was measured by quenching of fura-2 fluorescence, as described (21). Unless stated otherwise, all experiments were performed in the presence of extracellular Ca<sup>2+</sup> (1 mM CaCl<sub>2</sub> added to the buffer 3 min before stimuli). Basal [Ca<sup>2+</sup>]<sub>i</sub> in freshly loaded HL-60 cells was 117 ± 18 nM (mean ± standard deviation; 25 different preparations of cells). Basal [Ca<sup>2+</sup>]<sub>i</sub> in control cells and in pertussis toxin-treated HL-60 cells did not differ significantly (data not shown). Basal [Ca<sup>2+</sup>]<sub>i</sub> in human neutrophils was 102 ± 21 nM (mean ± standard deviation; seven different preparations of cells). Within 4 hr after loading of the HL-60 cells, basal [Ca<sup>2+</sup>]<sub>i</sub> did not rise by more than 20 nM, and the responsiveness to any of the stimuli studied did not change significantly during that time. In addition, there was little variation in the responsiveness to the various stimuli using different batches of HL-60 cells. Quantitative comparison of peak [Ca<sup>2+</sup>]<sub>i</sub> values in HL-60 cells (e.g., comparison of control cells versus antagonist- or pertussis toxin-treated cells) is based on the responses to stimuli in different aliquots of a given preparation of loaded HL-60 cells. For the generation of complex concentration-response curves (see Figs. 1–4), the following procedure was adopted. Immediately after an aliquot of HL-60 cells was challenged with a stimulus, the next aliquot of HL-60 cells was equilibrated to 37° in a water bath. After 2 min ([Ca<sup>2+</sup>]<sub>i</sub> values in the challenged aliquot of cells had already declined), the fresh aliquot was placed into the fluorometer, to assess basal [Ca<sup>2+</sup>]<sub>i</sub>. By this procedure, up to 80 aliquots of cells could be analyzed within 4 h. Due to the stability in the responsiveness of cells, agonist and/or antagonist concentrations were not randomized, but they were varied in a systematic manner by starting with agonists and/or antagonists at low concentrations.

**Labeling of phosphoinositides in HL-60 cells and measurement of inositol phosphate formation.** For labeling of phosphoinositides in HL-60 cells, cells were seeded at a density of 1 × 10<sup>6</sup> cells/ml in inositol-free RPMI 1640 medium supplemented with 10% (v/v) horse serum, 1% (v/v) nonessential amino acids, 2 mM L-glutamine, 50 units/ml penicillin, 50 μg/ml streptomycin, 0.2 mM Bt<sub>2</sub>cAMP, and 2–5 μCi/ml *myo*-[2-<sup>3</sup>H]inositol, in a humidified atmosphere with 7% CO<sub>2</sub> at 37°. Cells were cultured for 48 hr. Prelabeled cells were centrifuged at 250 × *g* for 10 min at 20°. Cells were suspended in the buffer used for the determination of [Ca<sup>2+</sup>]<sub>i</sub>. Cells were recentrifuged and were suspended in buffer. After another centrifugation of the cells, they were suspended at 1 × 10<sup>7</sup> cells/ml in buffer. Reactions were performed at 37° in the aforementioned buffer supplemented with 1 mM CaCl<sub>2</sub>, in a final volume of 200 μl. Reactions were initiated by addition of 100 μl of cells to 100 μl of buffer containing solvent (control) or stimulus at the desired concentration. Assays did not contain LiCl. Reactions were stopped after 30 sec by addition of 400 μl of a solution consisting of CHCl<sub>3</sub>, CH<sub>3</sub>OH, and concentrated HCl (100:200:1, v/v/v). Thereafter, 125 μl of CHCl<sub>3</sub> and 25 μl of H<sub>2</sub>O were added to the reaction mixtures. After centrifugation for phase separation, 350 μl of the aqueous phase were loaded on Dowex 1 × 8 columns (0.8 × 2 cm). Inositol phosphates were eluted as described (37). The eluates (8 ml) were mixed with 12 ml of Flow-szint IV scintillation fluid (Cambera Packard, Frankfurt/Main, Germany), and radioactivity was determined by scintillation counting.

**Assay for O<sub>2</sub><sup>-</sup> formation.** O<sub>2</sub><sup>-</sup> formation was monitored by continuous measurement of ferricytochrome *c* reduction that was inhibitable by superoxide dismutase, using an Uvikon 810 dual-beam spectrophotometer (Kontron, Eching, Germany) (12, 13). Reaction mixtures (0.5

ml) contained  $2.5 \times 10^6$  HL-60 cells, 100  $\mu$ M ferricytochrome c, and a buffer consisting of (in mM) 138 NaCl, 6 KCl, 1 MgCl<sub>2</sub>, 1 CaCl<sub>2</sub>, 5.5 glucose, and 20 HEPES-NaOH, pH 7.4. Reaction mixtures were incubated for 3 min at 37° before the addition of stimuli. The absolute amounts of O<sub>2</sub><sup>-</sup> generated were calculated.

**$\beta$ -Glucuronidase release.** Enzyme release was assessed as described (13). Briefly, HL-60 cells ( $5.0 \times 10^6$  cells in 0.5 ml) were suspended in the buffer used for the determination of O<sub>2</sub><sup>-</sup> formation. Cells were incubated for 5 min at 37° in the presence of cytochalasin B (5  $\mu$ g/ml) before the addition of stimuli. Reactions were conducted for 10 min and were terminated by placement of the tubes on ice. Reaction mixtures were centrifuged at  $1000 \times g$  for 10 min at 4°. The determinations of the activities of lactate dehydrogenase and  $\beta$ -glucuronidase in supernatant fluids of reaction mixtures and in cell lysates were performed as described (24). Lactate dehydrogenase release from cells generally amounted to <5% of cellular content (data not shown).


**Tyrosine phosphorylation.** Tyrosine phosphorylation of proteins was performed as described (35). In brief, HL-60 cells ( $1.0 \times 10^6$  cells in 40  $\mu$ l) were suspended in the buffer used for the determination of O<sub>2</sub><sup>-</sup> formation. Cells were incubated for 3 min at 37° before the addition of stimuli (20  $\mu$ l). Reactions were terminated after 1 min by addition of 30  $\mu$ l of lysis buffer [6% (w/v) sodium dodecyl sulfate, 18% (v/v) 2-mercaptoethanol, 30% (v/v) glycerol, 1 mM Na<sub>3</sub>VO<sub>4</sub>, and a trace amount of Bromophenol blue dye, in 0.2 M Tris-HCl, pH 7.5]. Samples were immediately incubated for 5 min at 95°. Thereafter, samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis on gels containing 9% (w/v) acrylamide. The separated proteins were then transferred onto nitrocellulose filters, which were saturated with ovalbumin. Filters were incubated for 1 hr with 1  $\mu$ g/ml monoclonal antiphototyrosine antibodies. Subsequently, filters were incubated with a goat anti-mouse IgG-peroxidase conjugate. Bound antibodies were detected by the enhanced chemiluminescence Western blotting detection system (Amersham, Braunschweig, Germany). Phosphotyrosine-containing proteins were detected by exposure to medical X-ray films (autoluminography).

**Calculations.** EC<sub>50</sub> and IC<sub>50</sub> values were obtained by graphically analyzing the concentration-response curves shown in Figs. 1–4. The pA<sub>2</sub> for diphenhydramine versus histamine (see Fig. 2B) was calculated as described (38, 39).


## Results

**Pertussis toxin partially inhibits histamine-induced rises in [Ca<sup>2+</sup>]<sub>i</sub> in HL-60 cells.** Concentration-response curves for the effects of fMet-Leu-Phe and histamine on [Ca<sup>2+</sup>]<sub>i</sub> in Bt<sub>2</sub>cAMP-differentiated HL-60 cells are shown in Fig. 1. fMet-Leu-Phe increased [Ca<sup>2+</sup>]<sub>i</sub> with an EC<sub>50</sub> of 3 nM and a maximum at 100 nM. Pertussis toxin decreased the effectiveness of fMet-Leu-Phe (1  $\mu$ M) by about 70% and reduced its potency by almost 10-fold. Histamine increased [Ca<sup>2+</sup>]<sub>i</sub> in a concentration-dependent manner as well; the EC<sub>50</sub> was 5  $\mu$ M and a plateau was reached at 30–100  $\mu$ M. The effectiveness of histamine (100  $\mu$ M) to increase [Ca<sup>2+</sup>]<sub>i</sub> was 30% of that of fMet-Leu-Phe (1  $\mu$ M). Pertussis toxin inhibited the effect of histamine (100  $\mu$ M) on [Ca<sup>2+</sup>]<sub>i</sub> by 35%.

**H<sub>1</sub> antagonists inhibit histamine-induced rises in [Ca<sup>2+</sup>]<sub>i</sub> in HL-60 cells.** Fig. 2A shows the effects of various H<sub>1</sub> antagonists on the concentration-response curve for histamine. Clemastine (a potent H<sub>1</sub> antagonist) (1, 2) at 100 nM abolished the stimulatory effects of histamine on [Ca<sup>2+</sup>]<sub>i</sub>. Chlorpheniramine, another potent H<sub>1</sub> antagonist (1, 2), at 100 nM reduced the effectiveness of histamine to increase [Ca<sup>2+</sup>]<sub>i</sub> by >70% and increased its EC<sub>50</sub> by about 2-fold. Impromidine (a potent H<sub>2</sub> agonist and H<sub>3</sub> antagonist and weak H<sub>1</sub> antagonist) (1, 2) at 100  $\mu$ M increased the EC<sub>50</sub> for histamine by almost 10-




**Fig. 1.** Concentration-response curves for fMet-Leu-Phe- and histamine-induced rises in [Ca<sup>2+</sup>]<sub>i</sub> in Bt<sub>2</sub>cAMP-differentiated HL-60 cells and effect of pertussis toxin. Bt<sub>2</sub>cAMP-differentiated HL-60 cells were treated with pertussis toxin (1  $\mu$ g/ml) or its vehicle (control) for 24 hr. Thereafter, cells were harvested and loaded with fura-2/AM, and the increases in [Ca<sup>2+</sup>]<sub>i</sub> induced by various substances were assessed. ■, Control cells; ●, pertussis toxin-treated cells. ○, fMet-Leu-Phe and histamine at the designated concentrations did not increase [Ca<sup>2+</sup>]<sub>i</sub>. Data shown are the means  $\pm$  standard deviations of six experiments performed with different preparations of HL-60 cells.




**Fig. 2.** Inhibition by chlorpheniramine, clemastine, diphenhydramine, and impromidine of histamine-induced rises in [Ca<sup>2+</sup>]<sub>i</sub> in Bt<sub>2</sub>cAMP-differentiated HL-60 cells. HL-60 cells were harvested and loaded with fura-2/AM, and the increases in [Ca<sup>2+</sup>]<sub>i</sub> induced by histamine at various concentrations, in the absence or presence of antagonists at fixed concentrations, were assessed. Antagonist or solvent (control) was added to cells 3 min before histamine. A, ●, Control; ◆, impromidine (100  $\mu$ M); ▲, chlorpheniramine (100 nM); ■, clemastine (100 nM). B, ●, Control; ▼, diphenhydramine (30 nM); ▲, diphenhydramine (100 nM); ■, diphenhydramine (300 nM); ◆, diphenhydramine (1  $\mu$ M); ►, diphenhydramine (3  $\mu$ M). ○, Histamine at the designated concentrations did not increase [Ca<sup>2+</sup>]<sub>i</sub>. Data shown are the means  $\pm$  standard deviations of four experiments performed with different preparations of HL-60 cells.

fold and reduced its effectiveness by about 20%. Diphenhydramine (1, 2, 40), another H<sub>1</sub> antagonist, at increasing fixed concentrations shifted the concentration-response curve for histamine to the right and substantially reduced the effectiveness of the agonist (Fig. 2B). The pA<sub>2</sub> for diphenhydramine was 7.9. Clemastine, chlorpheniramine, and diphenhydramine inhibited rises in [Ca<sup>2+</sup>]<sub>i</sub> induced by histamine (100  $\mu$ M) with IC<sub>50</sub> values of 3, 20, and 100 nM, respectively (Fig. 3). Impromidine was much less effective than the former substances, and famotidine (a potent H<sub>2</sub> antagonist) (41) was ineffective. Diphenhydramine, chlorpheniramine, clemastine, famotidine,





**Fig. 3.** Concentration-response curves for the inhibitory effects of clemastine, chlorpheniramine, diphenhydramine, impromidine, and famotidine on histamine-induced rises in  $[Ca^{2+}]_i$  in Bt<sub>2</sub>cAMP-differentiated HL-60 cells. HL-60 cells were harvested and loaded with fura-2/AM, and the increases in  $[Ca^{2+}]_i$  induced by histamine at a fixed concentration (100  $\mu$ M) in the presence of antagonists at various concentrations were assessed. In the absence of antagonists, histamine (100  $\mu$ M) increased  $[Ca^{2+}]_i$  by  $340 \pm 28$  nm (mean  $\pm$  standard deviation of four experiments performed with different preparations of HL-60 cells). Antagonists were added to cells 3 min before histamine. ●, Clemastine; ■, chlorpheniramine; ▲, diphenhydramine; ▼, impromidine; ◆, famotidine. ○, Antagonists at the indicated concentrations did not show an inhibitory effect on histamine-induced rises in  $[Ca^{2+}]_i$ . Data shown are the means of four experiments performed with different preparations of HL-60 cells. The standard deviation values of the data generally amounted to <10% of the means.



**Fig. 4.** Concentration-response curve for betahistine-induced rises in  $[Ca^{2+}]_i$  in Bt<sub>2</sub>cAMP-differentiated HL-60 cells and inhibition of the effect of betahistine by clemastine. Bt<sub>2</sub>cAMP-differentiated HL-60 cells were harvested and loaded with fura-2/AM, and the increases in  $[Ca^{2+}]_i$  induced by betahistine at various concentrations, in the absence or presence of clemastine, were assessed. Clemastine or solvent (control) was added to cells 3 min before betahistine. ●, Control; ■, clemastine (100 nM). Data shown are the means  $\pm$  standard deviations of three experiments performed with different preparations of HL-60 cells.


and impromidine, at up to 100  $\mu$ M, did not affect rises in  $[Ca^{2+}]_i$  induced by fMet-Leu-Phe (10 nM) (data not shown).

**Betahistine is a partial agonist to induce rises in  $[Ca^{2+}]_i$  in HL-60 cells.** Betahistine (a weak partial H<sub>1</sub> agonist) (1, 2) increased  $[Ca^{2+}]_i$  with an EC<sub>50</sub> of 30  $\mu$ M and a maximum at 100  $\mu$ M (Fig. 4). The effectiveness of betahistine to induce rises in  $[Ca^{2+}]_i$  amounted to <15% of that of histamine (100


$\mu$ M) (see Figs. 2 and 4). Clemastine (100 nM) abolished the effects of betahistine (see Fig. 4), whereas famotidine at up to 100  $\mu$ M was ineffective (data not shown). In contrast to betahistine, dimaprit and arpromidine (H<sub>2</sub> agonists) (1, 2, 42) and (*R*)- $\alpha$ -methylhistamine (an H<sub>3</sub> agonist) (1, 2), at up to 100  $\mu$ M, did not induce rises in  $[Ca^{2+}]_i$  (data not shown).

**Histamine activates nonselective cation channels in HL-60 cells.** In the presence of extracellular  $Ca^{2+}$ , fMet-Leu-Phe caused a rapid and large increase in  $[Ca^{2+}]_i$ , which returned to basal values within 15–20 min (Fig. 5); data shown only for up to 5 min). In comparison with fMet-Leu-Phe, histamine induced a considerably lower and more transient increase in  $[Ca^{2+}]_i$ , which was terminated within 3–5 min. In the absence of extracellular  $Ca^{2+}$ , the magnitude and duration of rises in  $[Ca^{2+}]_i$  induced by both substances were greatly reduced, suggesting that fMet-Leu-Phe and histamine increased  $[Ca^{2+}]_i$  predominantly through influx of  $Ca^{2+}$  from the extracellular space. The imidazole derivative SK&F 96365 is a blocker of nonselective cation channels and inhibits fMet-Leu-Phe-stimulated influxes of  $Ca^{2+}$  and  $Mn^{2+}$  in human neutrophils (22). In Bt<sub>2</sub>cAMP-differentiated HL-60 cells, SK&F 96365 (10  $\mu$ M) substantially reduced fMet-Leu-Phe- and histamine-induced  $Ca^{2+}$  influx (see Fig. 5). In contrast, SK&F 96365 did not inhibit mobilization of  $Ca^{2+}$  from intracellular stores.

Histamine-stimulated  $Mn^{2+}$  influx in HL-60 cells was measured by quenching of fura-2 fluorescence. At an excitation wavelength of 340 nm, fluorescence is increased by  $Ca^{2+}$  and is reduced by  $Mn^{2+}$ ; at an excitation wavelength of 360 nm, fluorescence is quenched by  $Mn^{2+}$  but is insensitive to changes in  $[Ca^{2+}]_i$  (21). At both excitation wavelengths,  $Mn^{2+}$  induced a slow decrease in fluorescence, indicating basal  $Mn^{2+}$  influx (Fig. 6). At an excitation wavelength of 340 nm but not 360 nm, histamine (100  $\mu$ M) transiently increased fluorescence,



**Fig. 5.** Effects of extracellular  $Ca^{2+}$  and of SK&F 96365 on fMet-Leu-Phe- and histamine-induced rises in  $[Ca^{2+}]_i$  in Bt<sub>2</sub>cAMP-differentiated HL-60 cells. HL-60 cells were harvested and loaded with fura-2/AM, and the increases in  $[Ca^{2+}]_i$  induced by fMet-Leu-Phe (100 nM) (A and B) and histamine (100  $\mu$ M) (C and D) were assessed. Arrows, addition of stimuli. Three minutes before stimuli, solvent (control) (A and C) or SK&F 96365 (10  $\mu$ M) (B and D) was added to cells. Trace 1, presence of  $CaCl_2$  (1 mM); trace 2, presence of EGTA (1 mM) without added  $CaCl_2$ . Superimposed original fluorescence tracings are shown. Similar results were obtained in three experiments performed with different preparations of HL-60 cells.



**Fig. 6.** Effects of histamine on  $Mn^{2+}$  influx in  $Bt_2cAMP$ -differentiated HL-60 cells. Cells were harvested and loaded with fura-2/AM, and fura-2 fluorescence was monitored at an excitation wavelength of 340 nm (trace 1) or 360 nm (trace 2). The emission wavelength was 500 nm. Experiments were performed in the absence of added  $CaCl_2$ . Arrows, addition of  $MnCl_2$  and histamine (100  $\mu M$  each). A, Experiments performed in the absence of SK&F 96365 (control); B, experiments performed in the presence of SK&F 96365 (10  $\mu M$ ). SK&F 96365 or solvent (control) was added to cells 3 min before  $MnCl_2$ . Superimposed original fluorescence tracings are shown. Similar results were obtained in three experiments performed with different preparations of HL-60 cells.

**TABLE 1**

**Effects of fMet-Leu-Phe and histamine on phosphoinositide degradation in  $Bt_2cAMP$ -differentiated HL-60 cells**

HL-60 cells were cultured for 48 hr in inositol-free RPMI medium supplemented with  $myo$ -[2- $^3H$ ]inositol and  $Bt_2cAMP$ , under the conditions described in Experimental Procedures. Thereafter, labeled cells were washed. HL-60 cells ( $1 \times 10^6$  cells in a volume of 200  $\mu l$ ) were exposed to solvent (control), fMet-Leu-Phe (1  $\mu M$ ), or histamine (100  $\mu M$ ) for 30 sec at 37°, in the buffer used for the determination of  $[Ca^{2+}]_i$  supplemented with 1 mM  $CaCl_2$ . Stopping of the reactions, extraction of inositol phosphates, and separation of inositol phosphates on Dowex 1  $\times$  8 columns were performed as described in Experimental Procedures. Data shown are the means  $\pm$  standard deviations of assay triplicates. Similar results were obtained in 10 experiments performed with different preparations of HL-60 cells.

Stimulus	Inositol phosphates <sup>a</sup>		
	InsP	InsP <sub>2</sub>	InsP <sub>3</sub>
	dpm		
Solvent (control)	789 $\pm$ 47	705 $\pm$ 46	159 $\pm$ 40
fMet-Leu-Phe	918 $\pm$ 165	1442 $\pm$ 40	407 $\pm$ 193
Histamine	925 $\pm$ 138	838 $\pm$ 169	192 $\pm$ 45

<sup>a</sup> InsP, inositol monophosphate; InsP<sub>2</sub>, inositol bisphosphate.

reflecting release of  $Ca^{2+}$  from intracellular stores. At excitation wavelengths of 340 and 360 nm, histamine substantially increased the rate of basal fluorescence quenching, reflecting  $Mn^{2+}$  influx. SK&F 96365 blocked histamine-induced  $Mn^{2+}$  influx but not  $Ca^{2+}$  mobilization from intracellular stores. Qualitatively the same results were obtained with fMet-Leu-Phe as stimulus (data not shown). Thus, histamine activates nonselective cation channels, as does fMet-Leu-Phe (see Figs. 5 and 6) (21, 22).


**Histamine activates phospholipase C in HL-60 cells.** Because small parts of fMet-Leu-Phe- and histamine-induced rises in  $[Ca^{2+}]_i$  were due to mobilization of  $Ca^{2+}$  from intracellular stores (see Fig. 5), the effects of these substances on phosphoinositide degradation were studied. fMet-Leu-Phe substantially stimulated inositol phosphate formation, in particular the formation of inositol bisphosphate and InsP<sub>3</sub> (Table 1).

In comparison with fMet-Leu-Phe, histamine only slightly stimulated formation of inositol phosphates.

**PMA differentially inhibits fMet-Leu-Phe- and histamine-induced rises in  $[Ca^{2+}]_i$  in HL-60 cells.** Brief exposure of neutrophilic cells to PMA, an activator of protein kinase C, inhibits fMet-Leu-Phe-induced phosphoinositide degradation and rises in  $[Ca^{2+}]_i$ , through uncoupling of receptors from G proteins and uncoupling of G proteins from effectors (9, 10, 14, 43). Treatment of HL-60 cells with PMA resulted in substantially diminished stimulatory effects of fMet-Leu-Phe on  $[Ca^{2+}]_i$  (Fig. 7). Partial resistance to inhibition by PMA of fMet-Leu-Phe-induced rises in  $[Ca^{2+}]_i$  in  $Bt_2cAMP$ -differentiated HL-60 cells was also reported in another study (14). In contrast, PMA abolished the stimulatory effects of histamine on  $[Ca^{2+}]_i$  (see Fig. 7). PDD, which does not activate protein kinase C, did not affect fMet-Leu-Phe- or histamine-induced rises in  $[Ca^{2+}]_i$ . These data indicate that the inhibitory effects of PMA on rises in  $[Ca^{2+}]_i$  were mediated via protein kinase C.

**Histamine does not stimulate  $O_2^-$  formation,  $\beta$ -glucuronidase release, and tyrosine phosphorylation in HL-60 cells.** In order to answer the question of whether histamine-induced rises in  $[Ca^{2+}]_i$  are linked to activation of specific cell functions, the effects of histamine on  $O_2^-$  formation and  $\beta$ -glucuronidase release were studied. fMet-Leu-Phe effectively activated  $O_2^-$  formation and  $\beta$ -glucuronidase release in HL-60 cells (Table 2). In contrast, histamine was devoid of any stimulatory effects. The lack of effect of histamine was also apparent in the presence of famotidine, i.e., when possible inhibitory effects of histamine, via H<sub>2</sub> receptors, on  $O_2^-$  formation and  $\beta$ -glucuronidase release were blocked (see Table 2) (27, 29, 30).

fMet-Leu-Phe-induced  $O_2^-$  formation is potentiated by ATP and UTP (12, 13, 24). However, histamine and betahistidine (0.1 and 1 mM each) did not potentiate  $O_2^-$  formation induced by fMet-Leu-Phe (30 nM and 1  $\mu M$ ) in  $Bt_2cAMP$ -differentiated HL-60 cells, regardless of the presence or absence of famotidine (10  $\mu M$ ) (data not shown). Similarly, histamine failed to potentiate fMet-Leu-Phe-induced  $\beta$ -glucuronidase release in




**Fig. 7.** Effects of PMA and PDD on fMet-Leu-Phe- and histamine-induced rises in  $[Ca^{2+}]_i$  in  $Bt_2cAMP$ -differentiated HL-60 cells. HL-60 cells were harvested and loaded with fura-2/AM, and the increases in  $[Ca^{2+}]_i$  induced by fMet-Leu-Phe (100 nM) (A–C) and histamine (100  $\mu M$ ) (D–F) were assessed. Arrows, addition of stimuli. Three minutes before stimuli, solvent (control) (A and D), PMA (100 ng/ml) (B and E), or PDD (100 ng/ml) (C and F) was added to cells. Superimposed original fluorescence tracings are shown. Similar results were obtained in three experiments performed with different preparations of HL-60 cells.

TABLE 2

**Effects of fMet-Leu-Phe and histamine on  $O_2^-$  formation and  $\beta$ -glucuronidase release in  $Bt_2cAMP$ -differentiated HL-60 cells**

$O_2^-$  formation and  $\beta$ -glucuronidase release in  $Bt_2cAMP$ -differentiated HL-60 cells were assessed in the presence of various stimuli. Famotidine was added to cells 3 min before histamine when  $O_2^-$  formation was assessed and 5 min before histamine when  $\beta$ -glucuronidase release was studied. Cytochalasin B (5  $\mu$ g/ml) was added to cells 5 min before stimuli when  $\beta$ -glucuronidase release was determined. For further experimental details, see Experimental Procedures. Data shown are the means  $\pm$  standard deviations of assay triplicates. Similar results were obtained in three experiments with different preparations of HL-60 cells.

Stimulus	$O_2^-$ formation	$\beta$ -Glucuronidase release
	nmol/ $10^6$ cells	% of cellular content
Solvent (control)	0	$5.2 \pm 0.5$
fMet-Leu-Phe (1 $\mu$ M)	$6.5 \pm 0.8$	$26.3 \pm 1.3$
Histamine (100 $\mu$ M)	0	$5.1 \pm 0.2$
Histamine (1 mM)	0	$4.9 \pm 0.4$
Histamine (100 $\mu$ M) + famotidine (10 $\mu$ M)	0	$5.3 \pm 0.6$



**Fig. 8.** Effects of fMet-Leu-Phe and histamine on tyrosine phosphorylation in  $Bt_2cAMP$ -differentiated HL-60 cells. Cells ( $1.0 \times 10^6$ /tube) were incubated with various stimuli for 1 min. Famotidine was added to cells 3 min before histamine. Proteins were analyzed as described in Experimental Procedures. The autoluminogram of a blot is shown. Lane 1, solvent (control); lane 2, fMet-Leu-Phe (1  $\mu$ M); lane 3, fMet-Leu-Phe (10  $\mu$ M); lane 4, histamine (100  $\mu$ M); lane 5, histamine (1 mM); lane 6, histamine (100  $\mu$ M) plus famotidine (10  $\mu$ M). Numbers on the left, molecular masses of marker proteins (kDa); DF, dye front. Similar results were obtained in three experiments performed with different preparations of HL-60 cells.

$Bt_2cAMP$ -differentiated HL-60 cells under various experimental conditions, whereas ATP and UTP synergize with fMet-Leu-Phe (data not shown) (13, 24).

Tyrosine phosphorylation is an important signal for the activation of  $O_2^-$  formation by fMet-Leu-Phe (10, 20). Thus, the question arose of whether the lack of stimulation by histamine of  $O_2^-$  formation was due to a lack of activation of tyrosine phosphorylation. fMet-Leu-Phe stimulated tyrosine phosphorylation of 100/110-kDa proteins in HL-60 cells (Fig. 8). In contrast, histamine failed to stimulate tyrosine phosphorylation, in the absence or presence of famotidine.

**Histamine and betahistidine do not induce rises in  $[Ca^{2+}]_i$  in neutrophils.** Finally, the effects of fMet-Leu-Phe, histamine, and betahistidine on  $[Ca^{2+}]_i$  in human neutrophils were studied. As was the case for  $Bt_2cAMP$ -differentiated HL-

60 cells, fMet-Leu-Phe (1  $\mu$ M) induced large increases in  $[Ca^{2+}]_i$  in human neutrophils (data not shown) (see Fig. 1). However, histamine and betahistidine (1  $\mu$ M to 1 mM each) consistently failed to reveal any stimulatory effect on  $[Ca^{2+}]_i$  in seven preparations of human neutrophils (data not shown).

## Discussion

**Functional  $H_1$  receptors coupled to pertussis toxin-sensitive G proteins are present in  $Bt_2cAMP$ -differentiated HL-60 cells.** Our data suggest that, in  $Bt_2cAMP$ -differentiated HL-60 cells,  $H_1$  receptors mediate increases in  $[Ca^{2+}]_i$ . This assumption is supported by several findings. Most importantly, histamine- and betahistidine-induced rises in  $[Ca^{2+}]_i$  were inhibited by  $H_1$  but not by  $H_2$  antagonists (see Figs. 2–4). Additionally, the  $pA_2$  for diphenhydramine versus histamine in  $Bt_2cAMP$ -differentiated HL-60 cells is in agreement with that obtained for other systems (see Fig. 2) (1, 40). The potency order of clemastine > chlorpheniramine > diphenhydramine >> impromidine, to inhibit the effects of histamine on  $[Ca^{2+}]_i$  in  $Bt_2cAMP$ -differentiated HL-60 cells, is in accordance with the classification of an  $H_1$  receptor as well (see Figs. 2 and 3) (1, 2, 40). Moreover, noncompetitive antagonism of clemastine, chlorpheniramine, and diphenhydramine with histamine at  $H_1$  receptors is documented in the literature (see Fig. 2) (1, 40). The lack of effect of  $H_1$  antagonists on fMet-Leu-Phe-induced rises in  $[Ca^{2+}]_i$  argues against nonspecific effects of these substances. Similarly to other systems, betahistidine is a weak partial  $H_1$  agonist in  $Bt_2cAMP$ -differentiated HL-60 cells, and  $H_2$  and  $H_3$  agonists failed to induce rises in  $[Ca^{2+}]_i$  (see Figs. 2 and 4) (1, 2).

As in other cell types (1–7),  $H_1$  receptors in  $Bt_2cAMP$ -differentiated HL-60 cells mediate activation of phospholipase C and increases in  $[Ca^{2+}]_i$  (see Fig. 1 and Table 1). The finding that histamine only marginally activated phosphoinositide degradation fits well with the fact that, in the absence of extracellular  $Ca^{2+}$ , histamine induced only small increases in  $[Ca^{2+}]_i$  (see Fig. 5 and Table 1). This increase presumably reflects  $InsP_3$ -mediated mobilization of  $Ca^{2+}$  from intracellular stores. The greatest part of histamine-induced rises in  $[Ca^{2+}]_i$  in HL-60 cells was attributable to activation of nonselective cation channels (see Figs. 5 and 6). Activation of cation channels via  $H_1$  receptors was also reported for other systems (2, 44).

$H_1$  receptor-mediated increases in  $[Ca^{2+}]_i$  in HL-60 cells were partially inhibited by pretreatment with pertussis toxin (see Fig. 1). These data indicate that, in these cells,  $H_1$  receptors interact with G proteins of the  $G_i$  family, as do formyl peptide receptors (8–10). Interestingly,  $H_1$  receptor-mediated increases in  $[Ca^{2+}]_i$  in HL-60 cells were more resistant to inhibition by pertussis toxin than were those induced by fMet-Leu-Phe (see Fig. 1). Thus, by analogy to ATP and UTP receptors,  $H_1$  receptors in HL-60 cells may interact with pertussis toxin-sensitive and pertussis toxin-insensitive G proteins (12–15).

**Histamine is an incomplete secretagogue.** In HL-60 cells, fMet-Leu-Phe and histamine activate phospholipase C and nonselective cation channels, resulting in increases in  $[Ca^{2+}]_i$  (see Figs. 5 and 6 and Table 1). There are, however, differences between fMet-Leu-Phe and histamine, i.e., fMet-Leu-Phe is substantially more effective than histamine in activating phospholipase C and inducing rises in  $[Ca^{2+}]_i$  (see Fig. 1 and Table 1). Unlike fMet-Leu-Phe, histamine did not stimulate  $O_2^-$  formation,  $\beta$ -glucuronidase release, and tyrosine phos-



phorylation (see Fig. 8 and Table 2). These data suggest that even maximal stimulation of H<sub>1</sub> receptors did not result in the generation of sufficiently high levels of intracellular signals to induce activation of specific cell functions, i.e., O<sub>2</sub><sup>-</sup> formation and enzyme release. There are differences in the pertussis toxin sensitivity of fMet-Leu-Phe- and histamine-induced rises in [Ca<sup>2+</sup>]<sub>i</sub> (see Fig. 1). Moreover, fMet-Leu-Phe- and histamine-induced rises in [Ca<sup>2+</sup>]<sub>i</sub> were differentially inhibited by PMA (see Fig. 7). These data point to differences in the interactions of H<sub>1</sub> and formyl peptide receptors with G proteins and in the subsequent interaction of G proteins with effectors. Taken together, fMet-Leu-Phe and histamine are functionally nonequivalent, and histamine is an incomplete secretagogue.

In addition to histamine, ATP, UTP, and leukotriene B<sub>4</sub> are incomplete secretagogues (12, 13, 23, 24, 45). Moreover, interaction of H<sub>1</sub>, ATP, and leukotriene B<sub>4</sub> receptors with G proteins differs from the interaction of formyl peptide receptors with G proteins (see Figs. 1 and 7) (12–15, 17). However, leukotriene B<sub>4</sub>, ATP, and UTP on one hand and histamine on the other hand are functionally nonequivalent. This view is supported by the findings that functional leukotriene B<sub>4</sub> receptors and ATP and UTP receptors are present not only in Bt<sub>2</sub>cAMP-differentiated HL-60 cells but also in human neutrophils (9, 10, 12–15, 18, 24). By comparison, there is no evidence for the existence of functional H<sub>1</sub> receptors in neutrophils, as assessed by measurement of [Ca<sup>2+</sup>]<sub>i</sub>. Furthermore, leukotriene B<sub>4</sub>, ATP, and UTP activate O<sub>2</sub><sup>-</sup> formation to at least a small degree or enhance the stimulatory effects of fMet-Leu-Phe on O<sub>2</sub><sup>-</sup> formation (12, 13, 23, 24). In contrast, histamine is devoid of any stimulatory effect on O<sub>2</sub><sup>-</sup> formation in neutrophils and in Bt<sub>2</sub>cAMP-differentiated HL-60 cells (see Table 3) (27, 29).

**What may be the regulatory importance of H<sub>1</sub> receptors in HL-60 cells?** In addition to Bt<sub>2</sub>cAMP-differentiated HL-60 cells, functional H<sub>1</sub> receptors are present in HL-60 promyelocytes, but there is no evidence to support the assumption that H<sub>1</sub> receptors play a role in the induction of differentiation of HL-60 cells (31). However, the absence of functional H<sub>1</sub> receptors in human neutrophils may point to an as yet unknown role of these receptors in the regulation of differentiation and/or proliferation (31). Interestingly, expression of H<sub>1</sub> receptors in cultured smooth muscle cells is also differentiation dependent (46). In addition, H<sub>1</sub> receptors may be involved in the regulation of proliferation of human fibroblasts, carcinoma cells, and melanoma cells (47, 48).

The possibility cannot be excluded that H<sub>1</sub> receptors in HL-60 cells are of no regulatory importance at all. It should be kept in mind that HL-60 cells are not normal myeloid cells but were derived from a patient with acute promyelocytic leukemia (49). Thus, the expression of functional H<sub>1</sub> receptors in Bt<sub>2</sub>cAMP-differentiated HL-60 cells could be a tumor cell-associated abnormality in signal transduction, rather than a phenomenon that occurs in normal neutrophils. Abnormalities in signal transduction processes in Bt<sub>2</sub>cAMP-differentiated HL-60 cells, in comparison with neutrophils, are not without precedence. First, ATP and UTP *per se* activate O<sub>2</sub><sup>-</sup> formation and β-glucuronidase release in Bt<sub>2</sub>cAMP-differentiated HL-60 cells but not in human neutrophils (12, 13, 24). Second, fMet-Leu-Phe induces β-glucuronidase release in Bt<sub>2</sub>cAMP-differentiated HL-60 cells in the absence of cytochalasin B but not in human neutrophils (13, 23, 24). Third, PMA stimulates β-glucuronidase release in Bt<sub>2</sub>cAMP-differentiated HL-60 cells but not in

neutrophils (13, 50). Finally, Bt<sub>2</sub>cAMP-differentiated HL-60 cells fail to express a cytosolic component of NADPH oxidase that is normally present in human neutrophils (51). Thus, caution must be exerted when results obtained with Bt<sub>2</sub>cAMP-differentiated HL-60 cells are extrapolated to human neutrophils.

In conclusion, histamine increases [Ca<sup>2+</sup>]<sub>i</sub> in Bt<sub>2</sub>cAMP-differentiated HL-60 cells via H<sub>1</sub> receptors coupled to pertussis toxin-sensitive G proteins and, possibly, to pertussis toxin-insensitive G proteins. Histamine is an incomplete secretagogue, inasmuch as it does not stimulate O<sub>2</sub><sup>-</sup> formation and β-glucuronidase release. Regardless of the regulatory importance of H<sub>1</sub> receptors in Bt<sub>2</sub>cAMP-differentiated HL-60 cells, this system provides a suitable model to study the pharmacology of H<sub>1</sub> receptors.

#### Acknowledgments

The authors are grateful to Dr. G. Schultz for helpful suggestions, to E. Bombien, E. Gäß, and E. Kanth for expert technical assistance, to J. Fischer for performing some preliminary experiments of this study, to Dr. E. Keller, Blutbank des Deutschen Roten Kreuzes, Berlin, for supplying buffy coats, to the laboratory staff of the Institut für Pharmakologie der Freien Universität Berlin for donating blood, and to Dr. K. Wenzel-Seifert for providing software to calculate [Ca<sup>2+</sup>]<sub>i</sub>.

#### References

- Buschauer, A., W. Schunack, J.-M. Arrang, M. Garbarg, J.-C. Schwartz, and J. M. Young. Histamine receptors, in *Clinical Pharmacology* (M. Williams, R. A. Glennon, and P. B. M. W. M. Timmermans, eds.), Vol. 13, Receptor Pharmacology and Function. Marcel Dekker, New York, 293–348 (1989).
- Hill, S. J. Distribution, properties, and functional characteristics of three classes of histamine receptors. *Pharmacol. Rev.* 42:45–83 (1990).
- Birnbaumer, L., J. Abramowitz, and A. M. Brown. Receptor-effector coupling by G proteins. *Biochim. Biophys. Acta* 1031:163–224 (1990).
- Nakahata, N., M. W. Martin, A. R. Hughes, J. R. Hepler, and T. K. Harden. H<sub>1</sub>-histamine receptors on human astrocytoma cells. *Mol. Pharmacol.* 29:188–195 (1986).
- Voyno-Yasenetskaya, T. A., M. P. Panchenko, E. V. Nupenko, V. O. Rybin, and V. A. Tkachuk. Histamine and bradykinin stimulate the phosphoinositide turnover in human umbilical vein endothelial cells via different G-proteins. *FEBS Lett.* 259:67–70 (1989).
- Murayama, T., Y. Kajiyama, and Y. Nomura. Histamine-stimulated and GTP-binding proteins-mediated phospholipase A<sub>2</sub> activation in rabbit platelets. *J. Biol. Chem.* 265:4290–4295 (1990).
- Raymond, J. R., F. J. Albers, J. P. Middleton, R. J. Lefkowitz, M. C. Caron, L. M. Obeid, and V. W. Dennis. 5-HT<sub>1A</sub> and histamine H<sub>1</sub> receptors in HeLa cells stimulate phosphoinositide hydrolysis and phosphate uptake via distinct G protein pools. *J. Biol. Chem.* 266:372–379 (1991).
- Rossi, F. The O<sub>2</sub><sup>-</sup>-forming NADPH oxidase of the phagocytes: nature, mechanisms of activation and function. *Biochim. Biophys. Acta* 853:65–89 (1986).
- Dillon, S. B., M. W. Verghese, and R. Snyderman. Signal transduction in cells following binding of chemoattractants to membrane receptors. *Virchows Arch. B Cell. Pathol.* 55:65–80 (1988).
- Seifert, R., and G. Schultz. The superoxide-forming NADPH oxidase of phagocytes: an enzyme system regulated by multiple mechanisms. *Rev. Physiol. Biochem. Pharmacol.* 117:1–332 (1991).
- Chaplinski, T. J., and J. E. Nield. Cyclic nucleotide-induced maturation of human promyelocytic leukemia cells. *J. Clin. Invest.* 70:953–964 (1982).
- Seifert, R., R. Burde, and G. Schultz. Activation of NADPH oxidase by purine and pyrimidine nucleotides involves G proteins and is potentiated by chemotactic peptides. *Biochem. J.* 259:813–819 (1989).
- Wenzel-Seifert, K., and R. Seifert. Neutrotide-, chemotactic peptide- and phorbol ester-induced exocytosis in HL-60 leukemic cells. *Immunobiology* 181:298–316 (1990).
- Dubyak, G. R., D. S. Cowen, and L. M. Meuller. Activation of inositol phospholipid breakdown in HL60 cells by P<sub>2</sub>-purinergic receptors for extracellular ATP: evidence for mediation by both pertussis toxin-sensitive and pertussis toxin-insensitive mechanisms. *J. Biol. Chem.* 263:18108–18117 (1988).
- Cowen, D. S., B. Baker, and G. R. Dubyak. Pertussis toxin produces differential inhibitory effects on basal, P<sub>2</sub>-purinergic, and chemotactic peptide-stimulated inositol phospholipid breakdown in HL-60 cells and HL-60 membranes. *J. Biol. Chem.* 265:16181–16189 (1990).
- Tohkin, M., N. Morishima, T. Iiri, K. Takahashi, M. Ui, and T. Katada. Interaction of guanine-nucleotide-binding regulatory proteins with chemotactic peptide receptors in differentiated human leukemic HL-60 cells. *Eur. J. Biochem.* 195:527–533 (1991).
- McLeish, K. R., P. Gierschik, T. Schepers, D. Sidiropoulos, and K. H. Jakobs. Evidence that activation of a common G-protein by receptors for leukotriene

- B<sub>4</sub> and *N*-formylmethionyl-leucyl-phenylalanine in HL-60 cells occurs by different mechanisms. *Biochem. J.* **260**:427–434 (1989).
18. Seifert, R., S. Serke, D. Huhn, W. Bessler, S. Hauschildt, J. Metzger, K.-H. Wiesmüller, and G. Jung. Incomplete differentiation of HL-60 leukemic cells by synthetic lipopeptides: partial inhibition by pertussis toxin of enhanced superoxide formation. *Eur. J. Biochem.* **203**:143–151 (1992).
  19. McLeish, K. R., P. Gierschik, and K. H. Jakobs. Desensitization uncouples the formyl peptide receptor-guanine nucleotide-binding protein interaction in HL60 cells. *Mol. Pharmacol.* **36**:384–390 (1989).
  20. Trudel, S., G. P. Downey, S. Grinstein, and M. R. Paquet. Activation of permeabilized HL60 cells by vanadate: evidence for divergent signalling pathways. *Biochem. J.* **269**:127–131 (1990).
  21. Merritt, J. E., R. Jacob, and T. J. Hallam. Use of manganese to discriminate between calcium influx and mobilization from internal stores in stimulated human neutrophils. *J. Biol. Chem.* **264**:1522–1527 (1989).
  22. Merritt, J. E., W. P. Armstrong, C. D. Benham, T. J. Hallam, R. Jacob, A. Jaza-Chamiec, B. K. Leigh, S. A. McCarthy, K. E. Moores, and T. J. Rink. SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. *Biochem. J.* **271**:515–522 (1990).
  23. Dewald, B., and M. Baggiolini. Platelet-activating factor as a stimulus of exocytosis in human neutrophils. *Biochim. Biophys. Acta* **888**:42–48 (1986).
  24. Seifert, R., K. Wenzel, F. Eckstein, and G. Schultz. Purine and pyrimidine nucleotides potentiate activation of NADPH oxidase and degranulation by chemotactic peptides and induce aggregation of human neutrophils via G proteins. *Eur. J. Biochem.* **181**:277–285 (1989).
  25. Gaspach, C., and J.-P. Abita. Human polymorphonuclear neutrophils: pharmacological characterization of histamine receptors mediating the elevation of cyclic AMP. *Mol. Pharmacol.* **21**:78–85 (1982).
  26. Gaspach, C., F. Saal, H. Cost, and J.-P. Abita. Identification and characterization of surface receptors for histamine in the human promyelocytic leukemia cell line HL-60: comparison with human peripheral neutrophils. *Mol. Pharmacol.* **22**:547–553 (1982).
  27. Seligmann, B. E., M. P. Fletcher, and J. I. Gallin. Histamine modulation of human neutrophil oxidative metabolism, locomotion, degranulation, and membrane potential changes. *J. Immunol.* **130**:1902–1909 (1983).
  28. Sawutz, D. G., K. Kalinyak, J. A. Whitsett, and C. L. Johnson. Histamine H<sub>2</sub> receptor desensitization in HL-60 human promyelocytic leukemia cells. *J. Pharmacol. Exp. Ther.* **231**:1–7 (1984).
  29. Burde, R., R. Seifert, A. Buschauer, and G. Schultz. Histamine inhibits activation of human neutrophils and HL-60 leukemic cells via H<sub>2</sub>-receptors. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **340**:671–678 (1989).
  30. Burde, R., A. Buschauer, and R. Seifert. Characterization of histamine H<sub>2</sub>-receptors in human neutrophils with a series of guanidine analogues of impromidine: are cell type-specific H<sub>2</sub>-receptors involved in the regulation of NADPH oxidase? *Naunyn-Schmiedeberg's Arch. Pharmacol.* **341**:455–461 (1990).
  31. Seifert, R., A. Höer, I. Schwaner, and A. Buschauer. Histamine increases cytosolic Ca<sup>2+</sup> in HL-60 promyelocytes predominantly via H<sub>2</sub> receptors with an unique agonist/antagonist profile and induces functional differentiation. *Mol. Pharmacol.* **42**:235–241 (1992).
  32. Wescott, S., and M. Kaliner. Histamine H-1 binding site on human polymorphonuclear leukocytes. *Inflammation* **7**:291–300 (1983).
  33. Cameron, W., K. Doyle, and R. E. Rocklin. Histamine type 1 (H<sub>1</sub>) receptor radioligand binding studies on normal T cell subsets, B cells, and monocytes. *J. Immunol.* **136**:2116–2120 (1986).
  34. Driver, A. G., C. A. Kukoly, and T. E. Bennett. Expression of histamine H<sub>1</sub> receptors on cultured histiocytic lymphoma cells. *Biochem. Pharmacol.* **38**:3083–3091 (1989).
  35. Offermanns, S., R. Seifert, J. W. Metzger, G. Jung, A. Lieberknecht, U. Schmidt, and G. Schultz. Lipopeptides are effective stimulators of tyrosine phosphorylation in human myeloid cells. *Biochem. J.* **282**:551–557 (1992).
  36. Grynkiewicz, G., M. Poenie, and R. Y. Tsien. A new generation of Ca<sup>2+</sup> indicators with greatly improved fluorescence properties. *J. Biol. Chem.* **260**:3440–3450 (1985).
  37. Berridge, M. J., R. M. C. Dawson, C. P. Downes, J. P. Heslop, and R. F. Irvine. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. *Biochem. J.* **212**:473–482 (1983).
  38. Tallarida, R. J., and R. B. Murray. pA<sub>2</sub> analysis. I. Schild plot, in *Manual of Pharmacologic Calculations with Computer Programs* (R. J. Tallarida and R. B. Murray, eds.) Ed. 2. Springer, Berlin, 53–56 (1987).
  39. van den Brink, F. G., and E. J. Lien. Competitive and noncompetitive antagonism. *Handb. Exp. Pharmacol.* **18**:333–335 (1978).
  40. Reinhardt, D., and U. Borchard. H<sub>1</sub>-receptor antagonists: comparative pharmacology and clinical use. *Klin. Wochenschr.* **60**:983–990 (1982).
  41. Schunack, W. What are the differences between H<sub>2</sub>-receptor antagonists? *Aliment. Pharmacol. Ther.* **1**:493S–503S (1987).
  42. Buschauer, A. Synthesis and *in vitro* pharmacology of arpromidine and related phenyl(pyridylalkyl)guanidines, a potential new class of positive inotropic drugs. *J. Med. Chem.* **32**:1963–1970 (1989).
  43. McCarthy, S. A., T. J. Hallam, and J. E. Merritt. Activation of protein kinase C in human neutrophils attenuates agonist-stimulated rises in cytosolic free Ca<sup>2+</sup> concentration by inhibiting bivalent-cation influx and intracellular Ca<sup>2+</sup> release in addition to stimulating Ca<sup>2+</sup> efflux. *Biochem. J.* **264**:357–364 (1989).
  44. Dickenson, J. M., and S. J. Hill. Histamine-stimulated increases in intracellular calcium in the smooth muscle cell line, DDT<sub>1</sub>MF-2. *Biochem. Pharmacol.* **42**:1545–1550 (1991).
  45. Hartiala, K. T., I. G. Scott, M. K. Viljanen, and K. E. O. Akerman. Lack of correlation between calcium mobilization and respiratory burst activation induced by chemotactic factors in rabbit polymorphonuclear leukocytes. *Biochem. Biophys. Res. Commun.* **144**:794–800 (1987).
  46. Mitsuhashi, M., and D. G. Payan. Receptor glycosylation regulates the affinity of histamine H<sub>1</sub> receptors during smooth muscle cell differentiation. *Mol. Pharmacol.* **35**:311–318 (1989).
  47. Johnson, C. L., C. G. Johnson, E. Bazan, D. Garver, E. Gruenstein, and M. Ahluwalia. Histamine receptors in human fibroblasts: inositol phosphates, Ca<sup>2+</sup> and cell growth. *Am. J. Physiol.* **258**:C533–C543 (1990).
  48. Tilly, B. C., L. G. J. Tertoolen, R. Remoore, A. Ladoux, I. Verlaan, S. W. de Laat, and W. H. Moolenaar. Histamine as a growth factor and chemoattractant for human carcinoma and melanoma cells: action through Ca<sup>2+</sup>-mobilizing H<sub>1</sub>-receptors. *J. Cell Biol.* **110**:1211–1215 (1990).
  49. Collins, S. J. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. *Blood* **70**:1233–1244 (1987).
  50. Baggiolini, M., and B. Dewald. Exocytosis by neutrophils, in *Regulation of Leukocyte Function* (R. E. Synderman, ed.). Plenum Press, New York, 221–246 (1984).
  51. Seifert, R., P. Jungblut, and G. Schultz. Differential expression of cytosolic activation factors for NADPH oxidase in HL-60 leukemic cells. *Biochem. Biophys. Res. Commun.* **161**:1109–1117 (1989).

Send reprint requests to: Dr. Roland Seifert, Institut für Pharmakologie, Universitätsklinikum Rudolf Virchow, Freie Universität Berlin, Thielallee 69/73, D-1000 Berlin 33, Germany.